Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 vipivotide tetraxetan + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) and pembrolizumab (Keytruda). Lutetium Lu 177 vipivotide tetraxetan is a PSMA-targeted radioligand therapy that delivers beta-particle radiation directly to prostate cancer cells expressing the prostate-specific membrane antigen (PSMA). Pembrolizumab is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, thereby enhancing the immune system's ability to detect and fight tumor cells. The combination is being investigated, specifically in a Phase 1b trial led by the University of California, San Francisco, to determine if the radioligand therapy can provide an immunogenic priming effect that increases the efficacy of the checkpoint inhibitor in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Brand names
- Pluvicto + Keytruda
- Other names
- lutetium Lu 177-psma-617-University of California, San Francisco-metastatic castration-resistant prostate cancer177Lu-PSMA-617 + pembrolizumab combination therapy
02
Targets
PSMA (Prostate-specific membrane antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on lutetium Lu 177 vipivotide tetraxetan + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 vipivotide tetraxetan + pembrolizumab.